Macromolecular therapeutics, particularly antibodies, are becoming more common and a greater proportion of the medical treatment space. As a result, the need for technology-based tools which can support and improve the research, competitive and legal intelligence processes has never been greater. Machine learning and AI are being increasingly leveraged as part of the research workflow, but how can they also be translated to the legal, licensing and commercial aspects of R&D? Assessing sequences through a data-rich IP intelligence lens can help elucidate competitive pressures, providing greater knowledge and better decision making. Through the ongoing, effective use of IP intelligence, commercially competitive macromolecules can be developed more quickly and cost effectively.

See IP Differently™: Visualizing macromolecular intellectual property to guide R&D, licensing, and legal strategies

ACS Spring Meeting 2021

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.